Selected highlights from the 5th Conference on Retroviruses and Opportunistic Infections.
Bartnof
H S
HS
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000517:prevention & control; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D048588:Benzoxazines; D002219:Carbamates; D002641:Chicago; D002986:Clinical Trials as Topic; D003226:Congresses as Topic; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000009:adverse effects / Q000627:therapeutic use; D004342:Drug Hypersensitivity; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use; D010078:Oxazines / Q000009:adverse effects / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D000099227:Abacavir
D000480:Alkynes; D019380:Anti-HIV Agents; D000998:Antiviral Agents; D048588:Benzoxazines; D002219:Carbamates; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D015507:Drugs, Investigational; D005663:Furans; D017320:HIV Protease Inhibitors; D006918:Hydroxyurea; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D000099227:Abacavir; C095108:amprenavir; C098320:efavirenz